TARSONS

Nov 8 (Reuters) - Tarsons Products Ltd TARO.NS:

• TARSONS PRODUCTS - COMMENCED COMMERCIAL PRODUCTION AT NEWLY SET UP PANCHLA PLANT

Source text: ID:nNSE32lmbg

Further company coverage: TARO.NS

(([email protected];;))

June 14 (Reuters) - Tarsons Products Ltd TARO.NS:

• TARSONS PRODUCTS LTD - MITSUBISHI UFJ FINANCIAL GROUP ACQUIRED INDIRECT INTEREST IN TARSONS PRODUCTS

• TARSONS PRODUCTS LTD - MUFG HAS AGGREGATED INTEREST IN TARSONS PRODUCTS OF 7.33% ORDINARY SHARE CAPITAL

Source text for Eikon: ID:nBSE3mDfpY

Further company coverage: TARO.NS

(([email protected];))

** Shares of labware products maker Tarsons Products TARO.NS rise 4.8% to 510.50 rupees

** Co through unit will acquire two German medical distributor entities namely- Nerbe R&D GmbH and Nerbe plus GmbH & Co. KG for 10-15 million euros (about $11-16 mln)

** More than 94,980 shares change hands nearly the same as the 30-day avg

** Five analysts covering the stock have an average rating of "buy"; median PT is 631 rupees, about 23% higher than the current price - LSEG data

** Stock down 26.6% so far this year

($1 = 0.9133 euros)

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

** Shares of Tarsons Products TARO.NS down as much as 2.3% to 485.05 rupees

** The labware products maker reported a 40.4% fall in Sept-qtr profit; revenue from operations down 6.9%

** Total expenses rose 11.7%, dragged by employee costs

** Stock trading below its 50-day, 100-day and 200-day moving average

** Stock currently down 2.2% further dragging YTD losses to 30%

($1 = 83.3150 Indian rupees)

(Reporting by Navamya Ganesh Acharya in Bengaluru)

(([email protected]; +91 8805175330 ;))

** ICICI Securities resumes coverage of India's Tarsons Products TARO.NS with "add" rating, sets TP of 590 rupees per share

** Brokerage bets on 11% upside to current price of 530 rupees on expansion into niche product areas

** Co maintaining strong margin profile against foreign and domestic rivals on premium pricing, tech prowess - ICICI

** Brokerage sees CAGR revenue growth of 10.7% over FY23-FY25

** All five analysts covering stock rate it "buy" or higher; median PT is 695 rupees - LSEG data

** Co's June-qtr results impacted by slow down in life science industry, higher inventory, which it sees persisting for a few quarters

** Stock down ~24% YTD

(Reporting by Archishma Iyer in Bengaluru)

(([email protected];))